country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-112450

Copy Link Print Information

Olomoucine II

Name: Olomoucine II
Brand: MedChemExpress
SKU: HY-112450
Price: 120.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Customer Review

Based on 1 Customer Validation

Olomoucine II is a potent CDK inhibitor with IC₅₀ values of 0.06, 0.1, 0.45, 7.6, 19.8 µM for CDK9/cyclin T, CDK2/cyclin E, CDK7/cyclin H, CDK1/cyclin B, CDK4/cyclin D1, respectively. Olomoucine II shows antiproliferative activity.

For research use only. We do not sell to patients.

CAS No.: 500735-47-7
Formula: C₁₉H₂₆N₆O₂
Molecular Weight:370.45

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Olomoucine II Chemical Structure

CAS No.: 500735-47-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Protocols (2)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

CDK9/cycT

0.06 μM (IC₅₀)

CDK2/cyclinE

0.1 μM (IC₅₀)

CDK7/cyclin H

0.45 μM (IC₅₀)

Cdk1/cyclin B

7.6 μM (IC₅₀)

CDK4/cyclinD1

19.8 μM (IC₅₀)

All CDK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
BJ	EC₅₀	5.4 μM Compound: olomoucine II	Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
CCRF-CEM	EC₅₀	8.1 μM Compound: olomoucine II	Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
CCRF-CEM	IC₅₀	3 μM Compound: Olomoucine II	In vitro cytotoxic effect on CEM cancer cell line In vitro cytotoxic effect on CEM cancer cell line	[PMID: 12392733]
CCRF-CEM	IC₅₀	7.4 μM Compound: Olomoucine II	Cytotoxicity against human CEM cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human CEM cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
G-361	IC₅₀	6.3 μM Compound: Olomoucine II	In vitro cytotoxic effect on G361 cancer cell line In vitro cytotoxic effect on G361 cancer cell line	[PMID: 12392733]
G-361	IC₅₀	9.2 μM Compound: Olomoucine II	Cytotoxicity against human G361 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human G361 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
HCT-116	IC₅₀	4.1 μM Compound: Olomoucine II	Cytotoxicity against human HCT116 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human HCT116 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
HeLa	EC₅₀	9.9 μM Compound: olomoucine II	Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
HOS	IC₅₀	10.6 μM Compound: Olomoucine II	Cytotoxicity against human HOS cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human HOS cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
HOS	IC₅₀	6.3 μM Compound: Olomoucine II	In vitro cytotoxic effect on HOS cancer cell line In vitro cytotoxic effect on HOS cancer cell line	[PMID: 12392733]
K562	IC₅₀	11.1 μM Compound: Olomoucine II	In vitro cytotoxic effect on K562 cancer cell line In vitro cytotoxic effect on K562 cancer cell line	[PMID: 12392733]
K562	IC₅₀	23 μM Compound: Olomoucine II	Cytotoxicity against human K562 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human K562 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
MCF7	EC₅₀	4.6 μM Compound: olomoucine II	Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
MCF7	IC₅₀	5.3 μM Compound: Olomoucine II	In vitro cytotoxic effect on MCF-7 cancer cell line In vitro cytotoxic effect on MCF-7 cancer cell line	[PMID: 12392733]
MCF7	IC₅₀	9.1 μM Compound: Olomoucine II	Cytotoxicity against human MCF7 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human MCF7 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
RPMI-8226	EC₅₀	6 μM Compound: olomoucine II	Cytotoxicity against human RPMI8226 cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human RPMI8226 cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
Sf9	IC₅₀	50 nM Compound: Olomoucine II	Inhibition of CDK2/Cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate Inhibition of CDK2/Cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate	[PMID: 22770608]
U-266	EC₅₀	7.2 μM Compound: olomoucine II	Cytotoxicity against human U266 cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human U266 cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]

In Vitro

Olomoucine II (72 h) shows antiproliferative activity with IC₅₀s of 9.3, 9.2, 10.5, 13.6, 5.0, 10.8, 5.3, 2.7, 16.3 µM for HOS, T98G, HBL100, BT474, MCF-7, HT-29, CCRF-CEM, BV173, HL60 cells, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Cell Proliferation Assay^[1]

View Protocol

Cell Line:

HOS, T98G, HBL100, BT474, MCF-7, HT-29, CCRF-CEM, BV173, HL60 cells
Concentration:
Incubation Time:

72 h
Result:

Showed antiproliferative activity with IC₅₀s of 9.3, 9.2, 10.5, 13.6, 5.0, 10.8, 5.3, 2.7, 16.3 µM for HOS, T98G, HBL100, BT474, MCF-7, HT-29, CCRF-CEM, BV173, HL60 cells, respectively.

Chemical Information

CAS No. 500735-47-7
Appearance Solid
Molecular Weight 370.45
Formula C₁₉H₂₆N₆O₂
Color White to off-white
SMILES

OC1=CC=CC=C1CNC2=C3N=CN(C(C)C)C3=NC(N[C@@H](CO)CC)=N2
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Protocols

All Cell Biology

Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Krystof V, et al. Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cell Mol Life Sci. 2005 Aug;62(15):1763-71. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote